Combined-Modality Therapy for Elderly Patients With Glioblastoma
This cohort study examines data on elderly patients with glioblastoma from the National Cancer Database to compare the association of overall survival with combined-modality therapy including...
View ArticleThe Age Factor in the Treatment of Glioblastoma
The world’s population is aging and rapidly increasing; it is estimated to reach 9.4 billion in 2050, with 1.5 billion people older than 65 years. In parallel to an aging population, cancer incidence...
View ArticleChemotherapy-Induced Peripheral Neuropathy and the Risk of Falling
This study explores the association between the symptoms of chemotherapy-induced peripheral neuropathy and the risk of falls for patients receiving neurotoxic chemotherapy.
View ArticleAutoimmune Encephalitis Following Immune Checkpoint Inhibitor Treatment
This case report describes the induction of autoimmune encephalitis in 2 patients after treatment of metastatic cancer with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab.
View ArticleNeurologic Immune-Related Adverse Events in Oncology Care
Immune-mediated therapies are unquestionably the most exciting wave of oncologic care in decades. For the first time in the history of multiple types of cancer, to our knowledge, investigators are...
View ArticleHippocampal Damage in Anti-LGI1 Encephalitis
This cross-sectional study evaluates structural changes noted on neuroimaging and cognitive outcomes in patients with leucine-rich, glioma-inactivated 1 protein encephalitis.
View ArticleRethinking Outcomes in Leucine-Rich, Glioma-Inactivated 1 Protein Encephalitis
The past decade has heralded an unprecedented expansion in knowledge concerning autoimmune-mediated central nervous system diseases, particularly those associated with autoantibodies against neuronal...
View ArticleHippocampal Damage in Anti-LGI1 Encephalitis
This cross-sectional study evaluates structural changes noted on neuroimaging and cognitive outcomes in patients with leucine-rich, glioma-inactivated 1 protein encephalitis.
View ArticleRethinking Outcomes in Leucine-Rich, Glioma-Inactivated 1 Protein Encephalitis
The past decade has heralded an unprecedented expansion in knowledge concerning autoimmune-mediated central nervous system diseases, particularly those associated with autoantibodies against neuronal...
View ArticleA Woman in Her 40s With Headache and New-Onset Seizures
This case report describes a woman in her 40s with a history of plasma cell leukemia who presented with 1 month of intermittent headaches followed by a seizure.
View ArticleThe Mystery of the Locking Eye
A 66-year-old woman with a history of a pituitary macroadenoma had intermittent diplopia of several years’ duration, iplopia was frequently present after repeatedly changing direction of gaze, and she...
View ArticleHematopoietic Stem Cell Transplant in Early-Stage Cerebral Adrenoleukodystrophy
This cohort study characterizes neurocognitive outcomes of boys with childhood cerebral adrenoleukodystrophy and early-stage cerebral disease who were treated with an allogeneic hematopoietic stem cell...
View ArticleGenetic Predisposition and Schwannoma or Meningioma in Children and Young...
This cohort study uses the database of the Manchester Centre for Genomic Medicine to analyze lymphocyte DNA of young patients who presented with meningioma or schwannoma before age 25 years.
View ArticleNeurological Complications Associated With Anti–Programmed Death 1 (PD-1)...
This cohort study investigates the frequency, clinical spectrum, and optimum treatment approach to neurological complications associated with anti–PD-1 inhibitor use.
View ArticleNeurological Complications of Immunotherapies—Beware of the Checkpoint Ahead
Neurological symptoms have been and continue to be one of the most common reasons for admission to a cancer center. Neurotoxic chemotherapy, direct invasion of cancer, and other neurological...
View Article